|Articles|July 1, 2015
The Transition from Paper Records to Electonic Batch Records
Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.
Advertisement
Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
2
How Mitigation and Maintenance Protect Against Future Risk
3
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
4
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
5
